Palvella Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
Palvella Therapeutics (NASDAQ:PVLA), a clinical-stage biopharmaceutical company developing therapies for rare genetic skin diseases, announced its participation in the Canaccord Genuity 45th Annual Growth Conference. The company's Founder and CEO, Wes Kaupinen, will engage in a fireside chat on August 12, 2025, at 1:00 p.m. ET.
The presentation will be accessible via live webcast on Palvella's website, with a replay available for approximately 90 days after the event. The company focuses on developing treatments for conditions that currently lack FDA-approved therapies.
Palvella Therapeutics (NASDAQ:PVLA), una societ脿 biofarmaceutica in fase clinica che sviluppa terapie per malattie genetiche rare della pelle, ha annunciato la sua partecipazione alla 45陋 Conferenza Annuale sulla Crescita di Canaccord Genuity. Il fondatore e CEO dell'azienda, Wes Kaupinen, parteciper脿 a una conversazione informale il 12 agosto 2025, alle 13:00 ET.
La presentazione sar脿 accessibile in diretta streaming sul sito web di Palvella, con la possibilit脿 di rivederla per circa 90 giorni dopo l'evento. L'azienda si concentra sullo sviluppo di trattamenti per condizioni attualmente prive di terapie approvate dalla FDA.
Palvella Therapeutics (NASDAQ:PVLA), una empresa biofarmac茅utica en etapa cl铆nica que desarrolla terapias para enfermedades gen茅ticas raras de la piel, anunci贸 su participaci贸n en la 45陋 Conferencia Anual de Crecimiento de Canaccord Genuity. El fundador y CEO de la compa帽铆a, Wes Kaupinen, participar谩 en una charla informal el 12 de agosto de 2025 a la 1:00 p.m. ET.
La presentaci贸n estar谩 disponible mediante una transmisi贸n en vivo en el sitio web de Palvella, con una repetici贸n accesible durante aproximadamente 90 d铆as despu茅s del evento. La empresa se enfoca en desarrollar tratamientos para condiciones que actualmente no cuentan con terapias aprobadas por la FDA.
Palvella Therapeutics (NASDAQ:PVLA)電� 頋穩 鞙犾爠 頂茧秬 歆堩櫂 旃橂鞝滊ゼ 臧滊皽頃橂姅 鞛勳儊 雼硠鞚� 氚旍澊鞓れ牅鞎� 須岇偓搿�, Canaccord Genuity 鞝�45須� 鞐半 靹膘灔 旎嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 須岇偓鞚� 彀诫鞛� 瓴� CEO鞚� Wes Kaupinen臧赌 2025雲� 8鞗� 12鞚� 鞓ろ泟 1鞁�(霃欕秬鞁滉皠)鞐� 頇旍儊 雽�頇旍棎 彀胳棳頃� 鞓堨爼鞛呺媹雼�.
氚滍憸電� Palvella 鞗轨偓鞚错姼毳� 韱淀暣 鞁れ嫓臧� 鞗轨簮鞀ろ姼搿� 鞝滉车霅橂┌, 頄夓偓 頉� 鞎� 90鞚� 霃欖晥 雼れ嫓氤搓赴 靹滊箘鞀るゼ 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟. 須岇偓電� 順勳灛 FDA 鞀轨澑 旃橂鞝滉岸� 鞐嗠姅 歆堩櫂鞐� 雽�頃� 旃橂鞝� 臧滊皽鞐� 歆戩頃橁碃 鞛堨姷雼堧嫟.
Palvella Therapeutics (NASDAQ:PVLA), une soci茅t茅 biopharmaceutique en phase clinique d茅veloppant des th茅rapies pour des maladies g茅n茅tiques rares de la peau, a annonc茅 sa participation 脿 la 45e conf茅rence annuelle sur la croissance de Canaccord Genuity. Le fondateur et PDG de l'entreprise, Wes Kaupinen, participera 脿 une discussion informelle le 12 ao没t 2025 脿 13h00 ET.
La pr茅sentation sera accessible via un webcast en direct sur le site web de Palvella, avec une rediffusion disponible pendant environ 90 jours apr猫s l'茅v茅nement. L'entreprise se concentre sur le d茅veloppement de traitements pour des maladies actuellement d茅pourvues de th茅rapies approuv茅es par la FDA.
Palvella Therapeutics (NASDAQ:PVLA), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, das Therapien f眉r seltene genetische Hautkrankheiten entwickelt, gab seine Teilnahme an der 45. j盲hrlichen Wachstumskonferenz von Canaccord Genuity bekannt. Der Gr眉nder und CEO des Unternehmens, Wes Kaupinen, wird am 12. August 2025 um 13:00 Uhr ET an einem Gespr盲ch am Kamin teilnehmen.
Die Pr盲sentation wird live 眉ber einen Webcast auf der Website von Palvella zug盲nglich sein, mit einer Wiederholung, die etwa 90 Tage nach der Veranstaltung verf眉gbar ist. Das Unternehmen konzentriert sich auf die Entwicklung von Behandlungen f眉r Erkrankungen, f眉r die derzeit keine von der FDA zugelassenen Therapien existieren.
- None.
- None.
WAYNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: PVLA) (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no Food and Drug Administration (FDA)-approved therapies, today announced that Wes Kaupinen, Founder and Chief Executive Officer of聽Palvella, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025, at 1:00 p.m. ET.
A live webcast of the fireside chat will be available on the聽聽section of Palvella's website at聽. An archived replay of the webcast will be available for approximately 90 days following the presentation.
About Palvella Therapeutics
Founded and led by rare disease drug development veterans, Palvella Therapeutics, Inc. (Nasdaq: PVLA) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies. Palvella is developing a broad pipeline of product candidates based on its patented QTORIN鈩� platform, with an initial focus on serious, rare genetic skin diseases, many of which are lifelong in nature. Palvella鈥檚 lead product candidate, QTORIN鈩�
颁辞苍迟补肠迟听滨苍蹿辞谤尘补迟颈辞苍
Investors
Wesley H. Kaupinen
Founder and CEO, Palvella Therapeutics
Media
Marcy Nanus
Managing Partner, Trilon Advisors, LLC
FAQ
When is Palvella Therapeutics (PVLA) presenting at the Canaccord Genuity Conference?
How can investors access Palvella Therapeutics' (PVLA) Canaccord conference presentation?
Who will be presenting for Palvella Therapeutics (PVLA) at the Canaccord conference?
What is Palvella Therapeutics' (PVLA) main business focus?
